Tvardi Therapeutics (69C) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

69C Analyst Ratings

Moderate Buy

5 Buy

0 Hold

1 Sell

Based on 6 analysts giving stock ratings to

Tvardi

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

69C Stock 12 Month Forecast

Average Price Target

€8.95

▲(645.83% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Tvardi Therapeutics in the last 3 months. The average price target is €8.95 with a high forecast of €12.99 and a low forecast of €2.60. The average price target represents a 645.83% change from the last price of €1.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"€16","33":"€33","-1":"-€1","7.5":"€7.5","24.5":"€24.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12.9918048,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€12.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.949909973333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€8.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.59836096,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,7.5,16,24.5,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.24,2.1439849846153844,3.0479699692307696,3.951954953846154,4.855939938461539,5.759924923076923,6.663909907692308,7.567894892307693,8.471879876923078,9.375864861538462,10.279849846153846,11.183834830769232,12.087819815384616,{"y":12.9918048,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.24,1.833069997948718,2.4261399958974357,3.019209993846154,3.612279991794872,4.20534998974359,4.7984199876923075,5.391489985641026,5.984559983589744,6.577629981538462,7.17069997948718,7.7637699774358975,8.356839975384615,{"y":8.949909973333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.24,1.3444893046153845,1.4489786092307693,1.5534679138461538,1.6579572184615383,1.762446523076923,1.8669358276923076,1.9714251323076923,2.075914436923077,2.1804037415384614,2.2848930461538464,2.389382350769231,2.4938716553846154,{"y":2.59836096,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.475,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.93,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.075,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.715,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.76,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.155,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.995,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€12.99

Average Price Target€8.95

Lowest Price Target€2.60

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Debanjana Chatterjee

JonesTrading

€10.39

Buy

766.12%

Upside

Reiterated

08/10/26

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (NASDAQ: SYRE), Stereotaxis (NYSE MKT: STXS) and Tvardi Therapeutics (NASDAQ: TVRD)

Etzer Darout

Barclays

€2.6

Sell

116.53%

Upside

Reiterated

08/07/26

Tvardi Therapeutics (TVRD) Gets a Sell from Barclays

Sara Nik

H.C. Wainwright

€7.8

Buy

549.59%

Upside

Reiterated

07/30/26

Analysts' Top Healthcare Picks: Tvardi Therapeutics (TVRD), Disc Medicine (IRON)

Yasmeen Rahimi

Piper Sandler

€11.26

Buy

838.30%

Upside

Upgraded

07/08/26

Tvardi Therapeutics upgraded to Overweight from Neutral at Piper SandlerTvardi Therapeutics upgraded to Overweight from Neutral at Piper Sandler

Ryan Deschner

Raymond James

€8.66

Buy

621.77%

Upside

Upgraded

07/08/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Tvardi Therapeutics (NASDAQ: TVRD), Resmed (NYSE: RMD) and Zimmer Biomet Holdings (NYSE: ZBH)

Julian Harrison

BTIG

€12.99

Buy

982.65%

Upside

Reiterated

07/07/26

Analysts Conflicted on These Healthcare Names: Cooper Co (NASDAQ: COO), Tvardi Therapeutics (NASDAQ: TVRD) and COMPASS Pathways (NASDAQ: CMPS)

Unknown Analyst

Cantor Fitzgerald

Not Ranked

Cantor Fitzgerald

―

Hold

―

Reiterated

05/11/26

Cantor Fitzgerald Sticks to Their Hold Rating for Tvardi Therapeutics (TVRD)

Jay Olson

Oppenheimer

€8.66

Buy

621.77%

Upside

Reiterated

05/11/26

Oppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)

Christopher Liu

Lucid Capital

€5.2

Buy

333.06%

Upside

Upgraded

02/04/26

Tvardi Therapeutics upgraded to Buy from Neutral at Lucid CapitalTvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Debanjana Chatterjee

JonesTrading

€10.39

Buy

766.12%

Upside

Reiterated

08/10/26

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (NASDAQ: SYRE), Stereotaxis (NYSE MKT: STXS) and Tvardi Therapeutics (NASDAQ: TVRD)

Etzer Darout

Barclays

€2.6

Sell

116.53%

Upside

Reiterated

08/07/26

Tvardi Therapeutics (TVRD) Gets a Sell from Barclays

Sara Nik

H.C. Wainwright

€7.8

Buy

549.59%

Upside

Reiterated

07/30/26

Analysts' Top Healthcare Picks: Tvardi Therapeutics (TVRD), Disc Medicine (IRON)

Yasmeen Rahimi

Piper Sandler

€11.26

Buy

838.30%

Upside

Upgraded

07/08/26

Tvardi Therapeutics upgraded to Overweight from Neutral at Piper SandlerTvardi Therapeutics upgraded to Overweight from Neutral at Piper Sandler

Ryan Deschner

Raymond James

€8.66

Buy

621.77%

Upside

Upgraded

07/08/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Tvardi Therapeutics (NASDAQ: TVRD), Resmed (NYSE: RMD) and Zimmer Biomet Holdings (NYSE: ZBH)

Julian Harrison

BTIG

€12.99

Buy

982.65%

Upside

Reiterated

07/07/26

Analysts Conflicted on These Healthcare Names: Cooper Co (NASDAQ: COO), Tvardi Therapeutics (NASDAQ: TVRD) and COMPASS Pathways (NASDAQ: CMPS)

Unknown Analyst

Cantor Fitzgerald

Not Ranked

Cantor Fitzgerald

―

Hold

―

Reiterated

05/11/26

Cantor Fitzgerald Sticks to Their Hold Rating for Tvardi Therapeutics (TVRD)

Jay Olson

Oppenheimer

€8.66

Buy

621.77%

Upside

Reiterated

05/11/26

Oppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)

Christopher Liu

Lucid Capital

€5.2

Buy

333.06%

Upside

Upgraded

02/04/26

Tvardi Therapeutics upgraded to Buy from Neutral at Lucid CapitalTvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tvardi Therapeutics

3 Months

Etzer DaroutBarclays

Success Rate

4/4 ratings generated profit

Average Return

+33.70%

Copying Etzer Darout's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +33.70% per trade.

1 Year

Etzer DaroutBarclays

Success Rate

4/4 ratings generated profit

Average Return

+43.43%

Copying Etzer Darout's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +43.43% per trade.

2 Years

Etzer DaroutBarclays

Success Rate

4/4 ratings generated profit

Average Return

+43.43%

Copying Etzer Darout's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +43.43% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

69C Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 69C has received 7 Buy Ratings, 0 Hold Ratings, and 3 Sell Ratings. 69C average Analyst price target in the past 3 months is 8.95.

Each month's total comprises the sum of three months' worth of ratings.

69C Financial Forecast

69C Earnings Forecast

Currently, no earnings data available.

69C Sales Forecast

Currently, no sales data available.

69C Stock Forecast FAQ

What is DE:69C’s average 12-month price target, according to analysts?

Based on analyst ratings, Tvardi Therapeutics’s 12-month average price target is 8.95.

What is DE:69C’s upside potential, based on the analysts’ average price target?

Tvardi Therapeutics has 645.83% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Tvardi Therapeutics a Buy, Sell or Hold?

Tvardi Therapeutics has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 0 hold ratings and 1 sell ratings.

What is Tvardi Therapeutics’s share price target?

The average share price target for Tvardi Therapeutics is 8.95. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €12.99 ,and the lowest forecast is €2.60. The average share price target represents 645.83% Increase from the current price of €1.2.

What do analysts say about Tvardi Therapeutics?

Tvardi Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of Tvardi Therapeutics?

To buy shares of DE:69C, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Tvardi Therapeutics (69C) Stock Forecast & Price Target

69C Analyst Ratings

69C Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Tvardi Therapeutics

69C Analyst Recommendation Trends

69C Financial Forecast

69C Earnings Forecast

69C Sales Forecast

69C Stock Forecast FAQ

Detailed List of Analyst Forecasts